Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Neoplasms, Squamous Cell

NCT03509467 2025-12-19

Using MC1R Genotype to Impact Melanoma Risk Behavior

Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Melanoma, Skin Neoplasms, Neoplasms, Basal Cell, Neoplasms, Squamous Cell

NCT04357873 2025-02-19

PEVOsq

Phase 2 Completed

112 enrolled

GastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Penile Neoplasms, Vulvar Neoplasms, Neoplasms, Squamous Cell

Clinical Trials

Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Using MC1R Genotype to Impact Melanoma Risk Behavior

PEVOsq

OESOCiTy

Primary Tumor Burden Score:A Novel Staging Parameter for ESCC After nCRT

PET-CT for Squamous Cell Carcinoma (SCC) of the Neck Nodes Unknown Primary Malignancy

Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer

Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)

Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)

Study of Sorafenib/Cetuximab in Head and Neck Cancer

Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy

Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer

Pemetrexed (Alimta) in Patients With Head and Neck Squamous Cell Cancer